Kamran Alam compensation by year
Taysha Gene Therapies Summary Compensation Table · all 6 fiscal years held| Component | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $142,088 | $390,000 | $401,700 | $413,751 | $455,126 | $473,331 |
| Bonus | $0 | $0 | $156,000 | $0 | $0 | $0 |
| Stock awards | $4,933,703 | — | $0 | $0 | $1,009,606 | $797,350 |
| Option awards | — | $1,412,006 | $498,215 | $402,039 | $832,482 | $607,710 |
| Non-equity incentive | $85,217 | $0 | $136,578 | $148,950 | $210,942 | $265,066 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $330,153 | $5,515 | $9,330 | $10,661 | $10,620 | $3,507 |
| Total | $5,491,161 | $1,807,521 | $1,201,823 | $975,401 | $2,518,777 | $2,146,964 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Taysha Gene Therapies, Inc. DEF 14A filed April 22, 2026, accession 0001193125-26-168525, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Taysha Gene Therapies, Inc. filed document, accession 0001193125-26-168525. Every figure is read from that document and cited to the page and table it appears in. Filed April 22, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 442,810 | $2,435,455 | — |
| RSU | 431,000 | $2,370,500 | — |
| RSU | 279,000 | $1,534,500 | — |
| RSU | 6,231 | $34,271 | — |
| Option | 43,721 | — | $1.18 |
| Option | 7,270 | — | $1.18 |
| Option | 307,507 | — | $1.71 |
| Option | 8,334 | — | $5.96 |
| Option | 3,334 | — | $6.52 |
| Option | 62,528 | — | $0.70 |
| Option | 431,000 | — | $1.85 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Taysha Gene Therapies, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Taysha Gene Therapies’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sean Nolan | Chief Executive Officer and Director | $4,099,065 |
| Kamran Alam · this page | Chief Financial Officer | $2,146,964 |
| Sukumar Nagendran | President and Head of Research and Development and Director | $2,092,890 |
Kamran Alam's compensation dossier, Taysha Gene Therapies
You have read Kamran Alam's totals and holdings. The dossier adds each equity grant Taysha Gene Therapies disclosed for Kamran Alam and Taysha Gene Therapies's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Taysha Gene Therapies compensation record
free company briefThis page is one person within Taysha Gene Therapies's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Taysha Gene Therapies's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Taysha Gene Therapies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TSHA
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.